Development of thermostable vaccine adjuvants

被引:12
|
作者
Qi, Yizhi [1 ]
Fox, Christopher B. [1 ,2 ]
机构
[1] Infect Dis Res Inst IDRI, 1616 Eastlake Ave E, Seattle, WA 98102 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Thermostable; vaccine adjuvant; lyophilization; spray drying; aluminum salts; emulsions; liposomes; nanoparticles; HEPATITIS-B-VACCINE; MESOPOROUS SILICA NANOPARTICLES; TRIVALENT INFLUENZA VACCINE; FREEZE-STABLE FORMULATION; DRY POWDER; DELIVERY-SYSTEM; SUBUNIT VACCINE; DOUBLE-BLIND; TUBERCULOSIS VACCINE; PROTECTIVE IMMUNITY;
D O I
10.1080/14760584.2021.1902314
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction The importance of vaccine thermostability has been discussed in the literature. Nevertheless, the challenge of developing thermostable vaccine adjuvants has sometimes not received appropriate emphasis. Adjuvants comprise an expansive range of particulate and molecular compositions, requiring innovative thermostable formulation and process development approaches. Areas covered Reports on efforts to develop thermostable adjuvant-containing vaccines have increased in recent years, and substantial progress has been made in enhancing the stability of the major classes of adjuvants. This narrative review summarizes the current status of thermostable vaccine adjuvant development and looks forward to the next potential developments in the field. Expert opinion As adjuvant-containing vaccines become more widely used, the unique challenges associated with developing thermostable adjuvant formulations merit increased attention. In particular, more focused efforts are needed to translate promising proof-of-concept technologies and formulations into clinical products.
引用
收藏
页码:497 / 517
页数:21
相关论文
共 50 条
  • [1] Adjuvants in tuberculosis vaccine development
    Moreno-Mendieta, Silvia A.
    Rocha-Zavaleta, Leticia
    Rodriguez-Sanoja, Romina
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2010, 58 (01): : 75 - 84
  • [2] Adjuvants and malaria vaccine development
    Xiao, LH
    Rafi-Janajreh, A
    Patterson, P
    Zhou, ZY
    Lal, AA
    [J]. MALARIA IMMUNOLOGY, 2ND EDITION, 2002, 80 : 343 - 365
  • [3] The development and use of vaccine Adjuvants
    Edelman, R
    [J]. MOLECULAR BIOTECHNOLOGY, 2002, 21 (02) : 129 - 148
  • [4] Novel adjuvants in vaccine development
    Kaufmann A.M.
    Schmidt-Ott R.
    Prechtl A.
    [J]. MMW - Fortschritte der Medizin, 2010, 152 (Suppl 4) : 115 - 118
  • [5] The development and use of vaccine adjuvants
    Robert Edelman
    [J]. Molecular Biotechnology, 2002, 21 : 129 - 148
  • [6] Toward the development of better vaccine adjuvants
    Ulmer, JB
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (02) : 119 - 121
  • [7] New horizons in adjuvants for vaccine development
    Reed, Steven G.
    Bertholet, Sylvie
    Coler, Rhea N.
    Friede, Martin
    [J]. TRENDS IN IMMUNOLOGY, 2009, 30 (01) : 23 - 32
  • [8] New horizons in adjuvants for vaccine development
    Reed, Steven G.
    Tomai, Mark
    Gale, Michael J., Jr.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2020, 65 : 97 - 101
  • [9] Prospects for the development of new vaccine adjuvants
    Cox, J
    Coulter, A
    [J]. BIODRUGS, 1999, 12 (06) : 439 - 453
  • [10] COPOLYMER ADJUVANTS IN MALARIA VACCINE DEVELOPMENT
    HUNTER, RL
    LAL, AA
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1994, 50 (04): : 52 - 58